Although it is now well established that PI3K (phosphoinositide 3-kinase) is a key enzyme in several intracellular processes, there are still relatively few reports that precisely identify the specific isoforms of PI3K actually involved in such events. The lack of specific inhibitors has made it particularly difficult to address the physiological roles of some isoforms, such as the members of class II. As a consequence, there is still relatively little understanding of the role of these enzymes and the question about the intracellular role of these isoforms still waits for more answers.
The PI3K (phosphoinositide 3-kinase) family
PI3Ks are a conserved family of lipid kinases that catalyse the phosphorylation of the D3 position of the inositol ring of phosphoinositides. The great interest around PI3Ks was mostly fuelled by the discovery that their products can interact with distinct structural domains and activate several proteins through their membrane targeting or modulation of their enzymatic activity. Therefore PI3Ks play key roles in different physiological events including cell proliferation, differentiation, apoptosis, cytoskeletal organization and membrane trafficking [1, 2] . Moreover, alterations in PI3K-dependent pathways are implicated in diseases such as cancer and diabetes [3] .
Although three classes of PI3Ks have been described [4, 5] , most of the intracellular functions were attributed to class I members even when data were obtained by using inhibitors that actually did not discriminate between the different isoforms. The discovery of class I PI3Ks was almost immediately followed by the identification of their main in vivo product, the lipid PtdIns(3,4,5)P 3 . Subsequent work demonstrated that PtdIns(3,4,5)P 3 has all the features of a 'canonical' intracellular second messenger, being generated only upon cellular stimulation and being able to bind several proteins involved in different intracellular functions, such as PKB (protein kinase B)/Akt. Furthermore, identification of a specific PtdIns(3,4,5)P 3 -switching off signal, the tumour suppressor PTEN (phosphatase and tensin homologue deleted on chromosome 10) [6] , increased the interest in class I PI3Ks and PtdIns(3,4,5)P 3 . In addition a precise mechanism of activation of such enzymes downstream to tyrosine kinases or Gprotein-coupled receptors was also described, allowing the generation of specific constitutively active and dominant-negative mutants which were fundamental to assess the role of these enzymes. Being the 'oldest' PI3K, the only PI3K isoform present in yeast [7] , class III PI3K Vps (vacuolar protein sorting protein 34) also received a relatively high attention and several studies addressed its intracellular roles, in particular in trafficking events. More recently, a renewed interest about the mammalian homologue has derived from the observation that this enzyme can be activated in a specific context [8, 9] .
Compared with class I and class III PI3Ks, much less is known about the class II PI3K members. Moreover, much information still needs to be translated into a precise physiological significance. As we discuss below, a quite good knowledge of their structural features has not resulted yet in a clear definition of their mechanism of activation. Similarly, an accurate analysis of their in vitro properties has not resulted in a precise definition of the in vivo product and this has definitively slowed down the identification of potential specific downstream effectors. Finally, identification of several stimuli able to activate them has not resulted in a precise definition of their intracellular functions.
Class II PI3Ks
Class II PI3Ks were identified using a PCR-based approach and primers corresponding to regions of strong homology in the lipid kinase domain of the known PI3Ks. A class II isoform was first identified in Drosophila melanogaster, named PI3K_68D [10] or Cpk [11] , and then in mouse [11, 12] . Human PI3K-C2α was cloned from the cell line U937 [13] ; human HsC2-PI3K (later named PI3K-C2β) was isolated from an MCF-7 breast tumour cell line cDNA library [14] and later from U937 [15] . Finally, a third isoform was identified almost simultaneously in human [16] , mouse [17] and rat [18] and named PI3K-C2γ . As for the human isoforms, Northern-blot analysis revealed that PI3K-C2α was widely expressed with the highest levels in the heart, placenta and ovary [13] . HsC2-PI3K/PI3K-C2β showed the highest expression in thymus and placenta [14] . Most of the human PI3K-C2γ was detected in liver and prostate samples but it appeared to be present in breast and salivary glands as well [16] . The wide distribution and the observation that class II PI3Ks appear as early as in Caenorhabditis elegans [19] strongly support a critical role of these isoforms in intracellular functions.
Structure
Class II PI3Ks are monomers of high molecular mass due to extensions at both the N-and C-termini. As with class I PI3Ks, they possess the Ras-binding, the C2-like, the PIK (phosphoinositide kinase) and the core kinase domains, but they lack the p85-binding domain. Extensions at the N-terminus are distinct between the different class II isoforms. HsC2-PI3K/PI3K-C2β [14] and PI3K_68D/Cpk [10, 11] , but not human [13] or murine PI3K-C2α [11] , possess 'canonical' proline-rich sequences in their N-terminal region, suggesting that these isoforms might specifically interact with SH3 domain (Src homology 3 domain)-containing proteins. Coiled coil domains and clathrin-binding domains are also present in some but not all isoforms. Extensions at the Cterminus are more conserved where all class II PI3Ks contain a PX domain (Phox homology domain) and a second C2 domain whose role is still undefined.
Features of the enzymes
Probably the most peculiar feature of class II PI3Ks is their sensitivity to the classical PI3K inhibitors wortmannin and LY294002. In particular the α isoform is very resistant to both inhibitors (IC 50 for wortmannin: 420 nM; IC 50 for LY294002: 19 µM compared with the corresponding 5 nM and 0.8 µM for p110α) [13] . Similarly, it was reported that endogenous PI3K-C2α from insulin-stimulated soleus muscles [20] or from VSMCs (vascular smooth-muscle cells) [21] was only partially (40-50 %) inhibited by 1 µM wortmannin. The β isoform appears to be very sensitive to wortmannin (IC 50 = 1.6 nM similar to class I PI3K) but quite resistant to LY294002 (IC 50 = 6.9 µM versus 1.2 µM for class I PI3K) [15, 22] . These results indicate that the classical PI3K inhibitors used so far are not able to discriminate between the different isoforms or to block all PI3K isoforms. Therefore assumptions that PI3K is not involved in specific intracellular pathways based on the use of such inhibitors should be reconsidered. One example is the TC10-dependent pathway in insulin signalling, previously reported as a PI3K-independent pathway based on the use of low concentrations of wortmannin [23] . We have previously demonstrated that a PI3K-dependent step is actually involved in this pathway [24] .
Localization
Endogenous PI3K-C2α is localized in the trans-Golgi network and low-density microsomes [25] . Interestingly, neither the PX domain nor the C-terminal C2 domain appeared to be necessary for this intracellular localization [25] . Most but not all PI3K-C2α-containing intracellular puncta are coincident with clathrin to which the enzyme is able to bind [26] . A peculiar nuclear localization at the levels of the nuclear speckles, subregion of nucleus containing premRNA, has also been reported [27] . In chromaffin cells, PI3K-C2α is present in a subpool of mature secretory granules proximal to the plasma membrane consistent with its role in neuroendocrine secretion [28] . Similarly, endogenous PI3K-C2β was found to be localized mainly in the lowdensity microsomal fraction with a small amount present at the plasma membrane and in the cytosolic fraction [15] . Nuclear localization was also reported for PI3K-C2β [29, 30] . Overexpressed PI3K-C2β in cells shows a punctuate distribution in the cytoplasm and it localizes to cell protrusions and ruffling regions of the plasma membrane [31] . We have recently reported that a Myc-tagged PI3K-C2β translocates to the plasma membrane upon stimulation with LPA (lysophosphatidic acid), suggesting that a stimulated recruitment to the plasma membrane might be involved in activation of the enzyme [22] . Recent evidence from our laboratory suggests that a stimulated targeting of the class II enzymes to the plasma membrane similar to the mechanism of activation of class I PI3K might be a more general mechanism of activation (M. Falasca and T. Maffucci, unpublished work).
Substrate specificity
Although it is generally assumed that class II PI3Ks can phosphorylate both PtdIns and PtdIns(4)P in vitro, it should be kept in mind that they actually possess a preferential in vitro activity for PtdIns, indicating that PtdIns(3)P is their main product in vitro [10, 12, 15, 17] . Interestingly, none among PI3K_68D [10, 11] , PI3K-C2α [13] , PI3K-C2β [15] or PI3K-C2γ [17] is able to phosphorylate PtdIns(4,5)P 2 in vitro. A slight activity towards PtdIns(4,5)P 2 was observed only in the presence of phosphatidylserine for PI3K-C2α [13] or in the presence of phosphatidylcholine, phosphatidylserine or phosphatidylethanolamine for PI3K-C2β but this was still only 1 % of the total PI3K activity [15] , making questionable the relevance of such an observation. Despite such evidence in vitro, the main in vivo substrate of class II PI3Ks has remained elusive for a long time. The possibility that PtdIns(3)P might be the in vivo product of such isoforms is supported by analyses performed by in vitro labelling of nuclear extracts [29, 30] . An attempt to identify the in vivo product of class II PI3Ks by metabolic labelling of cells and HPLC analysis has been made only recently through 3 H-labelling of PC12 cells (pheochromocytoma cells). Data indicate that overexpression of a kinase-dead PI3K-C2α in these cells reduces the basal levels of PtdIns(3)P [28] . Such results still did not identify the actual product of class II PI3Ks activation in vivo downstream to cellular stimulation. We have recently reported that specific down-regulation of PI3K-C2β by siRNA (small interfering RNA) completely inhibits the LPA-dependent generation of PtdIns(3)P monitored through overexpression of a PtdIns(3)P-binding protein [22] . Therefore these results suggested that PtdIns(3)P is likely to be the in vivo product of PI3K-C2β at least in the LPA signalling cascade [22] . Similarly, the observation that insulin generates a pool of PtdIns(3)P through activation of a PI3K more resistant to wortmannin and LY294002 than class I PI3K strongly suggests that PI3K-C2α might generate PtdIns(3)P in the insulin signalling [24] . A renewed interest in class II PI3Ks could be fuelled by recent evidence indicating that pools of PtdIns(3)P can be specifically generated upon cellular stimulation [22, 24, [32] [33] [34] and act as an intracellular second messenger [34] .
Activation and function
A growing list of stimuli has been found to be able to activate class II PI3Ks including (i) chemokines, such as MCP-1 (monocyte chemotactic protein-1) [35] , (ii) cytokines, such as leptin and TNFα (tumour necrosis factor α) [36] , and (iii) LPA [22] . Similarly, insulin was reported to activate PI3K-C2α in both insulin-responsive cells [37] and intact rat skeletal muscle [20] as well as PI3K-C2β [38] . Association of PI3K-C2α and PI3K-C2β with both EGF (epidermal growth factor) and PDGF (platelet-derived growth factor) receptors has also been reported, suggesting that both enzymes might have a role in such signalling pathways [39] . In addition PI3K-C2β has also been reported to associate with the SCF (stem cell factor) receptor [40] .
Despite such evidence suggesting a critical role of these isoforms in signalling, only few reports have actually revealed the physiological consequences of such an intracellular stimulation and defined the precise intracellular role of these enzymes. We have recently demonstrated that the specific LPA-dependent activation of PI3K-C2β is necessary for migration of ovarian and cervical cancer cells [22] . Interestingly, the observation that blockade of PtdIns(3)P results in inhibition of the LPA-dependent migration together with the effects of down-regulation of the enzyme on the intracellular localization of a PtdIns(3)P-binding probe strongly suggests that PtdIns(3)P might be the in vivo product of this enzyme in such a context [22] . A crucial role for PI3K-C2β in cell migration was subsequently confirmed by another study [41] . Similarly, the observation that overexpression of PI3K-C2β increases both the basal and the EGF-stimulated Rac1 activation whereas a catalytically inactive enzyme decreased the EGF-induced Rac1 activation suggests a potential intracellular role for the EGF-dependent activation of PI3K-C2β [31] . Interestingly, PI3K_68D is critical for patterning downstream to Notch and EGF signalling [42] .
As for the other stimuli, evidence indicates that the clathrin-dependent PI3K-C2α activation might be related to a role of the enzyme in clathrin assembly [43] and clathrinmediated trafficking [26] . More recently, it has been reported that impairment of PI3K-C2α specifically inhibits the ATPdependent priming of neurosecretory granule exocytosis [28] . Interestingly, similar effects were obtained by overexpressing a PtdIns(3)P-binding domain, suggesting that the in vivo product of this enzyme might be PtdIns(3)P in such a context [28] . A key role for PI3K-C2α in vascular smooth-muscle contraction has also been recently demonstrated by the observation that down-regulation of the enzyme inhibits the noradrenaline-induced contraction [21] . Much remains to be understood regarding the role and physiological consequence of class II PI3Ks activation in other signalling pathways such as the role of PI3K-C2α downstream to MCP-1, leptin, TNFα or insulin activation or the role of PI3K-C2β in SCF signalling.
Conclusions
Despite a growing interest on class II PI3Ks and accumulating information about such isoforms, still much remains to be understood about these enzymes. Most importantly, relatively little is known about the physiological roles of class II PI3Ks. Since such a lack of information is mostly due to the absence of specific inhibitors allowing us to discriminate between the different isoforms, it is likely that the use of knocking-down strategies and availability of specific class II PI3Ks inhibitors will prove particular useful in filling the gaps of our knowledge of these enzymes. In addition, a definitive identification of their in vivo product will help in identifying the potential downstream effectors and shed light on their intracellular roles. Finally, it would be necessary to reconsider most of the conclusions regarding the involvement of PI3K in several intracellular processes obtained by using inhibitors not able to discriminate between the different isoforms or to inhibit class II PI3Ks. Studies in progress in our laboratory are currently clarifying some of these crucial aspects.
